Teladoc Health (TDOC) Projected to Post Earnings on Wednesday

Teladoc Health (NYSE:TDOC) is projected to announce its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to announce earnings of ($0.2171) per share and revenue of $588.13 million for the quarter. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Individuals may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 5:00 PM ET.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The firm had revenue of $606.93 million for the quarter, compared to analysts’ expectations of $615.44 million. During the same quarter in the previous year, the company posted ($0.19) EPS. The company’s revenue was down 4.0% compared to the same quarter last year. On average, analysts expect Teladoc Health to post ($0.92) EPS for the current fiscal year and ($0.76) EPS for the next fiscal year.

Teladoc Health Trading Down 2.0%

Shares of TDOC opened at $6.21 on Tuesday. Teladoc Health has a 12-month low of $4.40 and a 12-month high of $9.89. The firm has a 50-day moving average price of $6.14 and a 200 day moving average price of $6.47. The firm has a market capitalization of $1.13 billion, a P/E ratio of -6.28 and a beta of 2.14.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles III sold 17,805 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $6.10, for a total transaction of $108,610.50. Following the completion of the transaction, the chief executive officer owned 465,535 shares of the company’s stock, valued at $2,839,763.50. This trade represents a 3.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Canaccord Genuity Group lowered their price objective on Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Bank of America raised their target price on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Finally, Citigroup reduced their target price on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research report on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.54.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.